The trial will enroll 40 patients across the United States who have not responded adequately to standard hypovolemic septic shock treatments and are taking vasopressor drugs.
VivaCel Bio Initiates Phase 3 Clinical Trial of VBI-S for the Treatment of Hypovolemic Septic Shock
Leave a comment
